LymphedemaV1, PascalFrancis, Curation, bibRecord, 000937

Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer

Identifieur interne : 000937 ( PascalFrancis/Curation ); précédent : 000936; suivant : 000938

Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer

Auteurs : Ian S. Dayes [Canada] ; Tim J. Whelan [Canada] ; Jim A. Julian [Canada] ; Sameer Parpia [Canada] ; Kathleen I. Pritchard [Canada] ; David Paul D'Souza [Royaume-Uni, Canada] ; Lyn Kligman [Royaume-Uni] ; Donna Reise [Canada] ; Linda Leblanc [États-Unis] ; Margaret L. Mcneely [Canada] ; Lee Manchul [Canada] ; Jennifer Wiernikowski [Canada] ; Mark N. Levine [Canada]

Source :

Journal of clinical oncology [ 0732-183X ] ; 2013.

RBID : Pascal:13-0357345

Descripteurs français

Pascal (Inist)
- Lymphoedème, Essai clinique, Randomisation, Cancer du sein, Lymphatique, Système lymphatique, Traitement, Homme, Femelle, Adulte, Femme, Cancérologie.
Wicri :
- topic : Homme, Adulte, Femme.

English descriptors

KwdEn :
- Adult, Breast cancer, Cancerology, Clinical trial, Female, Human, Lymphatic, Lymphatic system, Lymphedema, Randomization, Treatment, Woman.

Abstract

Purpose Because of its morbidity and chronicity, arm lymphedema remains a concerning complication of breast cancer treatment. Although massage-based decongestive therapy is often recommended, randomized trials have not consistently demonstrated benefit over more conservative measures. Patients and Methods Women previously treated for breast cancer with lymphedema were enrolled from six institutions. Volumes were calculated from circumference measurements. Patients with a minimum of 10% volume difference between their arms were randomly assigned to either compression garments (control) or daily manual lymphatic drainage and bandaging followed by compression garments (experimental). The primary outcome was percent reduction in excess arm volume from baseline to 6 weeks. Results A total of 103 women were randomly assigned, and 95 were evaluable. Mean reduction of excess arm volume was 29.0% in the experimental group and 22.6% in the control group (difference, 6.4%; 95% CI, -6.8% to 20.5%; P = .34). Absolute volume loss was 250 mL and 143 mL in the experimental and control groups, respectively (difference, 107 mL; 95% CI, 13 to 203 mL; P = .03). There was no difference between groups in the proportion of patients losing 50% or greater excess arm volume. Quality of life (Short Form-36 Health Survey) and arm function were not different between groups. Conclusion This trial was unable to demonstrate a significant improvement in lymphedema with decongestive therapy compared with a more conservative approach. The failure to detect a difference may have been a result of the relatively small size of our trial.

A01	`01`	`1`		`@0 0732-183X`
A03		`1`		`@0 J. clin. oncol.`
A05				`@2 31`
A06				`@2 30`
A08	`01`	`1`	`ENG`	`@1 Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer`
A11	`01`	`1`		`@1 DAYES (Ian S.)`
A11	`02`	`1`		`@1 WHELAN (Tim J.)`
A11	`03`	`1`		`@1 JULIAN (Jim A.)`
A11	`04`	`1`		`@1 PARPIA (Sameer)`
A11	`05`	`1`		`@1 PRITCHARD (Kathleen I.)`
A11	`06`	`1`		`@1 D'SOUZA (David Paul)`
A11	`07`	`1`		`@1 KLIGMAN (Lyn)`
A11	`08`	`1`		`@1 REISE (Donna)`
A11	`09`	`1`		`@1 LEBLANC (Linda)`
A11	`10`	`1`		`@1 MCNEELY (Margaret L.)`
A11	`11`	`1`		`@1 MANCHUL (Lee)`
A11	`12`	`1`		`@1 WIERNIKOWSKI (Jennifer)`
A11	`13`	`1`		`@1 LEVINE (Mark N.)`
A14	`01`			`@1 McMaster University @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 13 aut.`
A14	`02`			`@1 Ontario Clinical Oncology Group @3 CAN @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 13 aut.`
A14	`03`			`@1 Juravinski Cancer Centre @3 CAN @Z 1 aut. @Z 2 aut. @Z 13 aut.`
A14	`04`			`@1 Talspar Nursing Services @3 CAN @Z 8 aut.`
A14	`05`			`@1 Hamilton Health Sciences @2 Hamilton @3 CAN @Z 12 aut.`
A14	`06`			`@1 University of Toronto @3 CAN @Z 5 aut.`
A14	`07`			`@1 Odette Sunnybrook Cancer Centre @3 CAN @Z 5 aut.`
A14	`08`			`@1 University Health Network @2 Toronto @3 CAN @Z 11 aut.`
A14	`09`			`@1 London Regional Cancer Program @2 London @3 GBR @Z 6 aut. @Z 7 aut.`
A14	`10`			`@1 University of Western Ontario @2 London, Ontario @3 CAN @Z 6 aut.`
A14	`11`			`@1 Dr Leon Richard Oncology Centre @2 Moncton, New Brunswick @3 USA @Z 9 aut.`
A14	`12`			`@1 University of Alberta @3 CAN @Z 10 aut.`
A14	`13`			`@1 Cross Cancer Institute @2 Edmonton, Alberta @3 CAN @Z 10 aut.`
A20				`@1 3758-3763`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20094 @5 354000501029700060`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 13-0357345`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of clinical oncology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Purpose Because of its morbidity and chronicity, arm lymphedema remains a concerning complication of breast cancer treatment. Although massage-based decongestive therapy is often recommended, randomized trials have not consistently demonstrated benefit over more conservative measures. Patients and Methods Women previously treated for breast cancer with lymphedema were enrolled from six institutions. Volumes were calculated from circumference measurements. Patients with a minimum of 10% volume difference between their arms were randomly assigned to either compression garments (control) or daily manual lymphatic drainage and bandaging followed by compression garments (experimental). The primary outcome was percent reduction in excess arm volume from baseline to 6 weeks. Results A total of 103 women were randomly assigned, and 95 were evaluable. Mean reduction of excess arm volume was 29.0% in the experimental group and 22.6% in the control group (difference, 6.4%; 95% CI, -6.8% to 20.5%; P = .34). Absolute volume loss was 250 mL and 143 mL in the experimental and control groups, respectively (difference, 107 mL; 95% CI, 13 to 203 mL; P = .03). There was no difference between groups in the proportion of patients losing 50% or greater excess arm volume. Quality of life (Short Form-36 Health Survey) and arm function were not different between groups. Conclusion This trial was unable to demonstrate a significant improvement in lymphedema with decongestive therapy compared with a more conservative approach. The failure to detect a difference may have been a result of the relatively small size of our trial.
C02	`01`	`X`		`@0 002B04C`
C02	`02`	`X`		`@0 002B12B04`
C03	`01`	`X`	`FRE`	`@0 Lymphoedème @5 01`
C03	`01`	`X`	`ENG`	`@0 Lymphedema @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfedema @5 01`
C03	`02`	`X`	`FRE`	`@0 Essai clinique @5 02`
C03	`02`	`X`	`ENG`	`@0 Clinical trial @5 02`
C03	`02`	`X`	`SPA`	`@0 Ensayo clínico @5 02`
C03	`03`	`X`	`FRE`	`@0 Randomisation @5 03`
C03	`03`	`X`	`ENG`	`@0 Randomization @5 03`
C03	`03`	`X`	`SPA`	`@0 Aleatorización @5 03`
C03	`04`	`X`	`FRE`	`@0 Cancer du sein @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Breast cancer @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Cáncer del pecho @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Lymphatique @5 05`
C03	`05`	`X`	`ENG`	`@0 Lymphatic @5 05`
C03	`05`	`X`	`SPA`	`@0 Linfático @5 05`
C03	`06`	`X`	`FRE`	`@0 Système lymphatique @5 06`
C03	`06`	`X`	`ENG`	`@0 Lymphatic system @5 06`
C03	`06`	`X`	`SPA`	`@0 Sistema linfático @5 06`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 08`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 08`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 08`
C03	`08`	`X`	`FRE`	`@0 Homme @5 09`
C03	`08`	`X`	`ENG`	`@0 Human @5 09`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 09`
C03	`09`	`X`	`FRE`	`@0 Femelle @5 11`
C03	`09`	`X`	`ENG`	`@0 Female @5 11`
C03	`09`	`X`	`SPA`	`@0 Hembra @5 11`
C03	`10`	`X`	`FRE`	`@0 Adulte @5 12`
C03	`10`	`X`	`ENG`	`@0 Adult @5 12`
C03	`10`	`X`	`SPA`	`@0 Adulto @5 12`
C03	`11`	`X`	`FRE`	`@0 Femme @5 17`
C03	`11`	`X`	`ENG`	`@0 Woman @5 17`
C03	`11`	`X`	`SPA`	`@0 Mujer @5 17`
C03	`12`	`X`	`FRE`	`@0 Cancérologie @5 18`
C03	`12`	`X`	`ENG`	`@0 Cancerology @5 18`
C03	`12`	`X`	`SPA`	`@0 Cancerología @5 18`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie des vaisseaux lymphatiques @5 38`
C07	`02`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Linfático patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 39`
C07	`03`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 39`
C07	`03`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 39`
C07	`04`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`04`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`04`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`05`	`X`	`FRE`	`@0 Pathologie de la glande mammaire @2 NM @5 40`
C07	`05`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 40`
C07	`05`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 40`
C07	`06`	`X`	`FRE`	`@0 Pathologie du sein @2 NM @5 41`
C07	`06`	`X`	`ENG`	`@0 Breast disease @2 NM @5 41`
C07	`06`	`X`	`SPA`	`@0 Seno patología @2 NM @5 41`
N21				`@1 336`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000018

Links to Exploration step

Pascal:13-0357345

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer</title>
<author><name sortKey="Dayes, Ian S" sort="Dayes, Ian S" uniqKey="Dayes I" first="Ian S." last="Dayes">Ian S. Dayes</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Juravinski Cancer Centre</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Whelan, Tim J" sort="Whelan, Tim J" uniqKey="Whelan T" first="Tim J." last="Whelan">Tim J. Whelan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Juravinski Cancer Centre</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Julian, Jim A" sort="Julian, Jim A" uniqKey="Julian J" first="Jim A." last="Julian">Jim A. Julian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Parpia, Sameer" sort="Parpia, Sameer" uniqKey="Parpia S" first="Sameer" last="Parpia">Sameer Parpia</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Pritchard, Kathleen I" sort="Pritchard, Kathleen I" uniqKey="Pritchard K" first="Kathleen I." last="Pritchard">Kathleen I. Pritchard</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Toronto</s1>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Odette Sunnybrook Cancer Centre</s1>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="D Souza, David Paul" sort="D Souza, David Paul" uniqKey="D Souza D" first="David Paul" last="D'Souza">David Paul D'Souza</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>London Regional Cancer Program</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Kligman, Lyn" sort="Kligman, Lyn" uniqKey="Kligman L" first="Lyn" last="Kligman">Lyn Kligman</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>London Regional Cancer Program</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Reise, Donna" sort="Reise, Donna" uniqKey="Reise D" first="Donna" last="Reise">Donna Reise</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Talspar Nursing Services</s1>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Leblanc, Linda" sort="Leblanc, Linda" uniqKey="Leblanc L" first="Linda" last="Leblanc">Linda Leblanc</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Dr Leon Richard Oncology Centre</s1>
<s2>Moncton, New Brunswick</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mcneely, Margaret L" sort="Mcneely, Margaret L" uniqKey="Mcneely M" first="Margaret L." last="Mcneely">Margaret L. Mcneely</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>University of Alberta</s1>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Cross Cancer Institute</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Manchul, Lee" sort="Manchul, Lee" uniqKey="Manchul L" first="Lee" last="Manchul">Lee Manchul</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Wiernikowski, Jennifer" sort="Wiernikowski, Jennifer" uniqKey="Wiernikowski J" first="Jennifer" last="Wiernikowski">Jennifer Wiernikowski</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Hamilton Health Sciences</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Levine, Mark N" sort="Levine, Mark N" uniqKey="Levine M" first="Mark N." last="Levine">Mark N. Levine</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Juravinski Cancer Centre</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0357345</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0357345 INIST</idno>
<idno type="RBID">Pascal:13-0357345</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000018</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000937</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer</title>
<author><name sortKey="Dayes, Ian S" sort="Dayes, Ian S" uniqKey="Dayes I" first="Ian S." last="Dayes">Ian S. Dayes</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Juravinski Cancer Centre</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Whelan, Tim J" sort="Whelan, Tim J" uniqKey="Whelan T" first="Tim J." last="Whelan">Tim J. Whelan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Juravinski Cancer Centre</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Julian, Jim A" sort="Julian, Jim A" uniqKey="Julian J" first="Jim A." last="Julian">Jim A. Julian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Parpia, Sameer" sort="Parpia, Sameer" uniqKey="Parpia S" first="Sameer" last="Parpia">Sameer Parpia</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Pritchard, Kathleen I" sort="Pritchard, Kathleen I" uniqKey="Pritchard K" first="Kathleen I." last="Pritchard">Kathleen I. Pritchard</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Toronto</s1>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Odette Sunnybrook Cancer Centre</s1>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="D Souza, David Paul" sort="D Souza, David Paul" uniqKey="D Souza D" first="David Paul" last="D'Souza">David Paul D'Souza</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>London Regional Cancer Program</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Kligman, Lyn" sort="Kligman, Lyn" uniqKey="Kligman L" first="Lyn" last="Kligman">Lyn Kligman</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>London Regional Cancer Program</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Reise, Donna" sort="Reise, Donna" uniqKey="Reise D" first="Donna" last="Reise">Donna Reise</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Talspar Nursing Services</s1>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Leblanc, Linda" sort="Leblanc, Linda" uniqKey="Leblanc L" first="Linda" last="Leblanc">Linda Leblanc</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Dr Leon Richard Oncology Centre</s1>
<s2>Moncton, New Brunswick</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mcneely, Margaret L" sort="Mcneely, Margaret L" uniqKey="Mcneely M" first="Margaret L." last="Mcneely">Margaret L. Mcneely</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>University of Alberta</s1>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Cross Cancer Institute</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Manchul, Lee" sort="Manchul, Lee" uniqKey="Manchul L" first="Lee" last="Manchul">Lee Manchul</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Wiernikowski, Jennifer" sort="Wiernikowski, Jennifer" uniqKey="Wiernikowski J" first="Jennifer" last="Wiernikowski">Jennifer Wiernikowski</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Hamilton Health Sciences</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Levine, Mark N" sort="Levine, Mark N" uniqKey="Levine M" first="Mark N." last="Levine">Mark N. Levine</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Juravinski Cancer Centre</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Breast cancer</term>
<term>Cancerology</term>
<term>Clinical trial</term>
<term>Female</term>
<term>Human</term>
<term>Lymphatic</term>
<term>Lymphatic system</term>
<term>Lymphedema</term>
<term>Randomization</term>
<term>Treatment</term>
<term>Woman</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Essai clinique</term>
<term>Randomisation</term>
<term>Cancer du sein</term>
<term>Lymphatique</term>
<term>Système lymphatique</term>
<term>Traitement</term>
<term>Homme</term>
<term>Femelle</term>
<term>Adulte</term>
<term>Femme</term>
<term>Cancérologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Adulte</term>
<term>Femme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose Because of its morbidity and chronicity, arm lymphedema remains a concerning complication of breast cancer treatment. Although massage-based decongestive therapy is often recommended, randomized trials have not consistently demonstrated benefit over more conservative measures. Patients and Methods Women previously treated for breast cancer with lymphedema were enrolled from six institutions. Volumes were calculated from circumference measurements. Patients with a minimum of 10% volume difference between their arms were randomly assigned to either compression garments (control) or daily manual lymphatic drainage and bandaging followed by compression garments (experimental). The primary outcome was percent reduction in excess arm volume from baseline to 6 weeks. Results A total of 103 women were randomly assigned, and 95 were evaluable. Mean reduction of excess arm volume was 29.0% in the experimental group and 22.6% in the control group (difference, 6.4%; 95% CI, -6.8% to 20.5%; P = .34). Absolute volume loss was 250 mL and 143 mL in the experimental and control groups, respectively (difference, 107 mL; 95% CI, 13 to 203 mL; P = .03). There was no difference between groups in the proportion of patients losing 50% or greater excess arm volume. Quality of life (Short Form-36 Health Survey) and arm function were not different between groups. Conclusion This trial was unable to demonstrate a significant improvement in lymphedema with decongestive therapy compared with a more conservative approach. The failure to detect a difference may have been a result of the relatively small size of our trial.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. oncol.</s0>
</fA03>
<fA05><s2>31</s2>
</fA05>
<fA06><s2>30</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DAYES (Ian S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WHELAN (Tim J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JULIAN (Jim A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PARPIA (Sameer)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PRITCHARD (Kathleen I.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>D'SOUZA (David Paul)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KLIGMAN (Lyn)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>REISE (Donna)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>LEBLANC (Linda)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MCNEELY (Margaret L.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MANCHUL (Lee)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>WIERNIKOWSKI (Jennifer)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>LEVINE (Mark N.)</s1>
</fA11>
<fA14 i1="01"><s1>McMaster University</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Ontario Clinical Oncology Group</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Juravinski Cancer Centre</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Talspar Nursing Services</s1>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Hamilton Health Sciences</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>University of Toronto</s1>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Odette Sunnybrook Cancer Centre</s1>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>London Regional Cancer Program</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Dr Leon Richard Oncology Centre</s1>
<s2>Moncton, New Brunswick</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>University of Alberta</s1>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Cross Cancer Institute</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>3758-3763</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20094</s2>
<s5>354000501029700060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0357345</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose Because of its morbidity and chronicity, arm lymphedema remains a concerning complication of breast cancer treatment. Although massage-based decongestive therapy is often recommended, randomized trials have not consistently demonstrated benefit over more conservative measures. Patients and Methods Women previously treated for breast cancer with lymphedema were enrolled from six institutions. Volumes were calculated from circumference measurements. Patients with a minimum of 10% volume difference between their arms were randomly assigned to either compression garments (control) or daily manual lymphatic drainage and bandaging followed by compression garments (experimental). The primary outcome was percent reduction in excess arm volume from baseline to 6 weeks. Results A total of 103 women were randomly assigned, and 95 were evaluable. Mean reduction of excess arm volume was 29.0% in the experimental group and 22.6% in the control group (difference, 6.4%; 95% CI, -6.8% to 20.5%; P = .34). Absolute volume loss was 250 mL and 143 mL in the experimental and control groups, respectively (difference, 107 mL; 95% CI, 13 to 203 mL; P = .03). There was no difference between groups in the proportion of patients losing 50% or greater excess arm volume. Quality of life (Short Form-36 Health Survey) and arm function were not different between groups. Conclusion This trial was unable to demonstrate a significant improvement in lymphedema with decongestive therapy compared with a more conservative approach. The failure to detect a difference may have been a result of the relatively small size of our trial.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04C</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12B04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Randomization</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Breast cancer</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lymphatique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Lymphatic</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Linfático</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Système lymphatique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Lymphatic system</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Sistema linfático</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Femelle</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Female</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hembra</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Adulte</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Adult</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Adulto</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Femme</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Woman</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Mujer</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Breast disease</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Seno patología</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fN21><s1>336</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000937 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000937 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:13-0357345
   |texte=   Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer

Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri